Avalyn Pharma Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, null, null, null, null ], "ebit_estimate": [ -112.24, -113.43, -129.64, -147.3, -160.8 ], "ebitda_estimate": [ -111.14, -103.21, -124.3, null, null ], "net_income_estimate": [ -108.28, -104.65, -114.79, -147.3, -160.8 ], "per_share_eps_estimate": [ -2.37, -2.39, -2.33, -2.54, -2.56 ], "eps_nri_estimate": [ -2.73, -2.18, -2.08, -2.54, -2.56 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ -0.37, 4.87, 3.12, null, null ], "pretax_income_estimate": [ -108.28, -104.65, -114.79, -147.3, -160.8 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ null, -72.75, -45.67, null, null ], "gross_margin_estimate": [ null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -4.16, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -11.21, "future_ebitda_estimate_growth": -8.91, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -8.98, "future_pretax_income_estimate_growth": -8.98, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612" ], "revenue_estimate": [ null, null, null ], "ebit_estimate": [ -28.2, -28.5, -28.8 ], "ebitda_estimate": [ null, null, null ], "net_income_estimate": [ -28.2, -28.5, -28.8 ], "per_share_eps_estimate": [ -0.53, -0.54, -0.54 ], "eps_nri_estimate": [ -0.78, -0.53, -0.53 ], "dividend_estimate": [ null, null, null ], "book_value_per_share_estimate": [ null, null, null ], "pretax_income_estimate": [ -28.2, -28.5, -28.8 ], "operating_cash_flow_per_share_estimate": [ null, null, null ], "roa_estimate": [ null, null, null ], "roe_estimate": [ null, null, null ], "gross_margin_estimate": [ null, null, null ], "operating_cash_flow_estimate": [ null, null, null ], "pettm_estimate": [ 0, 0, 0 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -4.16, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -11.21, "future_ebitda_estimate_growth": -8.91, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -8.98, "future_pretax_income_estimate_growth": -8.98, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }